Shark Tooth Biotech

Shark Tooth is a mission-driven company focused on developing treatments for Charcot Marie Tooth Disease Type 1A (CMT1A) and other neuropathies. Unlike traditional drug discovery, Shark Tooth employs a 'Drug Assembly' model, partnering with laboratories to fund research that tests existing proprietary RNA technologies for their potential application in treating CMT1A. This approach leverages advancements in RNA chemistry and delivery, aiming to reduce toxicity and create viable treatment options. The company was founded by a father whose son is affected by CMT1A, a rare yet prevalent neuropathy impacting 1.6 million people globally. Shark Tooth's business model has been validated through partnerships, with their first candidate undergoing bio-distribution assessment in mice. The company operates in the biotech sector, primarily serving the unmet needs of individuals with CMT1A. Revenue is generated through investments and tax-deductible donations, which are crucial for advancing their mission. With guidance from scientific advisors from prestigious institutions like Harvard and Johns Hopkins, Shark Tooth is strategically positioned to accelerate the development of treatments for CMT1A.

Keywords: RNA, CMT1A, neuropathies, Drug Assembly, partnerships, research funding, biotech, rare disease, treatment development, mission-driven.